EMEA-001465-PIP01-13-M02

Key facts

Invented name
Evotaz
Active substance
  • Atazanavir (sulphate)
  • cobicistat
Therapeutic area
Infectious diseases
Decision number
P/0009/2018
PIP number
EMEA-001465-PIP01-13-M02
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG
Tel. +44 (0)1895 523740
E-mail: medical.information@bms.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating